Bristol Myers Squibb Company $BMY Shares Acquired by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA grew its stake in Bristol Myers Squibb Company (NYSE:BMY) by 0.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,035,236 shares of the biopharmaceutical company’s stock after purchasing an additional 8,549 shares during the period. Pictet Asset Management Holding SA owned approximately 0.10% of Bristol Myers Squibb worth $127,002,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of BMY. Primecap Management Co. CA purchased a new position in Bristol Myers Squibb in the 2nd quarter valued at $1,436,115,000. Legal & General Group Plc acquired a new position in Bristol Myers Squibb in the 2nd quarter valued at $980,862,000. BlackRock Inc. increased its stake in Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after buying an additional 8,702,106 shares during the period. State Street Corp raised its position in Bristol Myers Squibb by 7.3% during the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock worth $6,093,755,000 after buying an additional 7,192,724 shares during the last quarter. Finally, Caisse de depot et placement du Quebec purchased a new position in Bristol Myers Squibb during the 2nd quarter worth $243,646,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on BMY. William Blair restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, October 12th. Cantor Fitzgerald dropped their price target on shares of Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating on the stock in a research note on Thursday, October 8th. BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Jefferies Financial Group reissued a “buy” rating and set a $76.00 price target on shares of Bristol Myers Squibb in a report on Monday, October 12th. Finally, Morgan Stanley reduced their price objective on shares of Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating for the company in a research report on Friday, October 30th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $65.46.

Bristol Myers Squibb Trading Up 0.1%

NYSE:BMY opened at $62.20 on Monday. The stock has a fifty day moving average price of $62.34 and a two-hundred day moving average price of $60.11. The stock has a market capitalization of $127.15 billion, a price-to-earnings ratio of 13.79, a PEG ratio of 0.32 and a beta of 0.20. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.44 and a current ratio of 1.59. Bristol Myers Squibb Company has a 1 year low of $45.26 and a 1 year high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.10 by $0.25. The company had revenue of $13.07 billion for the quarter, compared to analyst estimates of $12.72 billion. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The business’s revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.63 EPS. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.45 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were paid a $0.63 dividend. The ex-dividend date was Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.88%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
• Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
• Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
• Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
• Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Insider Activity

In other Bristol Myers Squibb news, Director Julia A. Haller sold 3,800 shares of the company’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the transaction, the director directly owned 30,279 shares in the company, valued at approximately $1,916,963.49. This represents a 11.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Phil M. Holzer sold 500 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.05% of the stock is owned by company insiders.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.